Are new weight-loss drugs driving the first drop in obesity?
Core argument: Newly released data finds the US adult obesity rate fell by around two percentage points between 2020 and 2023, following decades of rising obesity rates worldwide.
Around the world, obesity rates have been stubbornly climbing for decades, if anything accelerating in recent years. But now newly released data finds that the US adult obesity rate fell by around two percentage points between 2020 and 2023. We have known for several years from clinical trials that Ozempic, Wegovy, and the new generation of diabetes and weight loss drugs produce large and sustained reductions in body weight. Now with mass public usage taking off — one in eight US adults have used the drugs, with 6% current users — the results may be showing up at the population level. While we can’t be certain that the new generation of drugs is behind this reversal, it is highly likely. For one, the decline is steepest among college graduates, the group most likely to be using them.

